건선 치료제 시장 규모, 점유율, 예측, 동향 분석, 치료별, 질환별 - 세계 예측(-2031년)

Psoriasis Treatment Market Size, Share, Forecast, & Trends Analysis By Treatment (TNF Inhibitor, Interleukin, Corticosteroids, Calcitriol, Retinoids, Calcineurin, Methotrexate) Disease (Plaque Psoriasis, Psoriatic Arthritis) - Global Forecast to 2031

The psoriasis treatment market is expected to reach $35.07 billion by 2031, at a CAGR of 9.8% from 2024 to 2031.

Following thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, opportunities, and trends.

The growth of this market is driven by factors such as the high burden of psoriasis, advancements in treatment options & diagnosis methods, a better understanding of disease pathogenesis, and the rising prevalence of psoriasis among the aging population. Additionally, increasing awareness of psoriasis, the rising utilization of combination therapies, and ongoing research on psoriasis are expected to create market growth opportunities.

Based on treatment type, the market is segmented into biologic drugs, topical treatments, and systemic treatments. The biologics drugs segment is projected to witness the highest growth rate of 7.4% during the forecast period of 2024-2031. The growth of this segment is driven by the increasing adoption of Interleukin inhibitors over conventional systemic medications due to their enhanced effectiveness and improved safety profile. Additionally, ongoing advancements in biologic drugs and initiatives by market players to introduce new biologic treatments for psoriasis are contributing to the segment's growth. For instance, in March 2023, Eli Lilly and Company (U.S.) launched Copellor, an interleukin inhibitor specifically designed for treating psoriasis, in India.

Based on disease type, the psoriasis treatment market is segmented into plaque psoriasis, psoriatic arthritis, and others. The psoriatic arthritis segment is expected to record the highest CAGR during the forecast period of 2024-2031. This segment's growth is driven by the increasing prevalence of psoriatic arthritis among patients with plaque psoriasis, growing awareness about the condition, and advancements in treatment for managing the disease.

Based on administration route, the global psoriasis treatment market is segmented into oral, topical, and injectable. The injectable segment is projected to register the highest CAGR during the forecast period of 2024-2031. This segment is driven by the increasing adoption of biologic therapies, which are mainly administered via injections, advancements in injection technology such as prefilled syringes and autoinjectors, and the increasing availability and accessibility of injectable medications through various distribution channels, including specialty pharmacies and online platforms.

Based on distribution channel, the global psoriasis treatment market is segmented into hospital pharmacies, retail pharmacies, and online/e-commerce platforms. The online/e-commerce platforms segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to the proliferation of e-commerce platforms, the rapid pace of digitalization, and the convenience of online shopping. These platforms provide a wide range of products, enabling patients to easily compare prices, read reviews, and access information about various treatment options.

An in-depth analysis of the geographical scenario of the psoriasis treatment market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the global psoriasis treatment market, followed by Europe and Asia-Pacific. North America's significant market share can be attributed to the high prevalence of psoriasis, widespread adoption of personalized therapies, advanced health infrastructure, and ongoing research and development efforts focused on psoriasis. These efforts have resulted in new treatment approaches and drugs being continuously developed and introduced to the market.

Key companies operating in the global psoriasis treatment market are AbbVie Inc. (U.S.), AstraZenca Plc (U.K.), Boehringer Ingelheim (Germany), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson and Johnson (U.S.), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Biogen, Inc. (U.S.), LEO Pharma A/S (Denmark), Sun Pharmaceutical Industries Ltd. (India), and Dr. Reddy's Laboratories Ltd. (India).

Scope of the Report:

Psoriasis Treatment Market Assessment-by Treatment Type

• Biologic Drugs
  • TNF Inhibitors
• Infliximab
• Adalimumab
• Etanercept
• Other TNF Inhibitors
  • Interleukin Inhibitors
• Guselkumab
• Risankizumab
• Tildrakizumab
  • Other Biologic Drugs (Anakinra, Basiliximab, Daclizumab, and Briakinumab, among others)
• Topical Treatments
  • Corticosteroids
• Hydrocortisone
• Desonide
• Betamethasone
• Other Corticosteroids
  • Vitamin D Analogs
• Calcitriol
• Calcipotriol
• Tacalcitol
  • Retinoids
  • Calcineurin Inhibitors
• Systemic Treatments
  • Methotrexate
  • Cyclosporine
  • Acitretin
  • Other Systemic Drugs (Apremilast, Cyclosporine, Adalimumab, Ustekinumab, Etanercept, Tofacitinib, and Tildrakizumab, among others)

Psoriasis Treatment Market Assessment-by Disease Type

• Plaque Psoriasis
• Psoriatic Arthritis
• Other Psoriasis Types (Guttate Psoriasis, Pustular Psoriasis, Inverse Psoriasis, and Erythrodermic Psoriasis)

Psoriasis Treatment Market Assessment-by Administration Route

• Oral
• Topical
• Injectable

Psoriasis Treatment Market Assessment-by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online/E-commerce Platforms

Psoriasis Treatment Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Poland
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

TABLE OF CONTENTS

1. Overview

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency and Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Drivers
    • 4.2.1.1. High Burden of Psoriasis
    • 4.2.1.2. Advancements in Treatment Options
    • 4.2.1.3. Improved Psoriasis Diagnosis
    • 4.2.1.4. Elderly People More Susceptible to Psoriasis
  • 4.2.2. Restraints
    • 4.2.2.1. High Costs of Psoriasis Treatments
    • 4.2.2.2. Side Effects of Medications
  • 4.2.3. Opportunities
    • 4.2.3.1. Rising Awareness Regarding Psoriasis
    • 4.2.3.2. Growing Use of Combination Therapies for Treatment
    • 4.2.3.3. Growing Research Regarding Psoriasis
  • 4.2.4. Challenges
    • 4.2.4.1. Stringent Regulatory & Approval Process of Drugs
• 4.3. Trends
  • 4.3.1. Targeted Therapies
  • 4.3.2. Steroid-free Topicals
• 4.4. Factor Analysis
• 4.5. Product Pipeline Analysis
• 4.6. Regulatory Analysis
• 4.7. Porter's Five Forces Analysis
• 4.8. Fundings & Investments Analysis

5. Psoriasis Treatment Market Assessment-by Test Type

• 5.1. Overview
• 5.2. Biologic Drugs
  • 5.2.1. TNF Inhibitors
    • 5.2.1.1. Infliximab
    • 5.2.1.2. Adalimumab
    • 5.2.1.3. Etanercept
    • 5.2.1.4. Other TNF Inhibitors
  • 5.2.2. Interleukin Inhibitors
    • 5.2.2.1. Guselkumab
    • 5.2.2.2. Risankizumab
    • 5.2.2.3. Tildrakizumab
  • 5.2.3. Other Biologic Drugs
• 5.3. Topical Treatments
  • 5.3.1. Corticosteroids
    • 5.3.1.1. Hydrocortisone
    • 5.3.1.2. Desonide
    • 5.3.1.3. Betamethasone
    • 5.3.1.4. Other Corticosteroids
  • 5.3.2. Vitamin D Analogs
    • 5.3.2.1. Calcitrol
    • 5.3.2.2. Calcipotriol
    • 5.3.2.3. Tacalcitol
  • 5.3.3. Retinoids
  • 5.3.4. Calcineurin Inhibitors
• 5.4. Systemic Treatments
  • 5.4.1. Methotrexate
  • 5.4.2. Cyclosporine
  • 5.4.3. Acitretin
  • 5.4.4. Other Systemic Treatments

6. Psoriasis Treatment Market Assessment-by Disease Type

• 6.1. Overview
• 6.2. Plaque Psoriasis
• 6.3. Psoriatic Arthritis
• 6.4. Other Types

7. Psoriasis Treatment Market Assessment-by Administration Route

• 7.1. Overview
• 7.2. Oral
• 7.3. Topical
• 7.4. Injectable

8. Psoriasis Treatment Market Assessment- by Distribution Channel

• 8.1. Overview
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Online/E-commerce Platforms

9. Psoriasis Treatment Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Netherlands
  • 9.3.7. Switzerland
  • 9.3.8. Poland
  • 9.3.9. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. India
  • 9.4.3. Japan
  • 9.4.4. Australia
  • 9.4.5. New Zealand
  • 9.4.6. Rest of Asia-Pacific
• 9.5. Latin America
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Share Analysis/ Market Ranking Analysis, by Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

• 11.1. AbbVie Inc. (U.S.)
• 11.2. AstraZenca Plc (U.K.)
• 11.3. Boehringer Ingelheim (Germany)
• 11.4. Celgene Corporation (U.S.)
• 11.5. Eli Lilly and Company (U.S.)
• 11.6. Johnson and Johnson (U.S.)
• 11.7. Merck KGaA (Germany)
• 11.8. Novartis AG (Switzerland)
• 11.9. Pfizer Inc. (U.S.)
• 11.10. Takeda Pharmaceutical Company Limited (Japan)
• 11.11. Biogen, Inc. (U.S.)
• 11.12. LEO Pharma A/S (Denmark)
• 11.13. Sun Pharmaceutical Industries Ltd. (India)
• 11.14. Dr. Reddy's Laboratories Ltd. (India)

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports